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Cardiovascular implant mineralization involving bioprosthetic materials, such as 
glutaraldehyde cross linked porcine aortic valves or synthetic materials such as 
polyurethanes, is an important problem that frequently leads to clinical failure of 
bioprosthetic heart valves, and complicates long-term experimental artificial heart device 
implants. Novel, proprietary, calcification resistant polyetherurethanes (PEU) as an 
alternative to bioprosthetic materials were the subject of these investigations. A series 
of PEU was derivatized through a proprietary reaction mechanism to achieve covalent 
binding of 100 to 500 nM/mg of bisphosphonate (2-hydroxyethane bisphosphonic acid, 
HEBP). The stability of HEBP (physically dispersed or covalently bound) verified by 
studying the release kinetics in physiological buffer (pH 7.4) at 37 'C, demonstrated the 
covalent binding reaction to be stable, efficient, and permanent. Surface (FTIR-ATR, 
ESCA, SEM/EDX) and bulk (solubility, GPC) properties demonstrated that the covalent 
binding of HEBP occurs in the soft segment of the PEU, reduces surface degradation, 
and does not affect the original material properties of the PEU (prior to derivatization). 
In vitro calcium diffusion of the derivatized PEU showed a decrease in calcium 
permeation as the concentration of HEBP covalent binding was increased. In vivo 
properties of underivatized and derivatized PEU (containing 100 nM of covalently bound 
HEBP) were studied with rat subdermal implants for 60 days. Explants demonstrated 
calcification resistance due to the covalently bound HEBP without any side effects. It is 
concluded that a PEU containing HEBP might serve as a calcification resistant candidate 
material for the fabrication of a heart valve prosthesis and other implantable devices. 
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Segmented polyurethane copolymers are well known 
medical grade elastomers that are frequently used in fabri- 
cating various blood contacting devices due to this 
material's versatile properties such as blood compatibility, 
hydrolytic stability, superior abrasion resistance, excellent 
physical strength, and high flexural endurance.'-3 These 
attributes of polyurethane result from the microphase 
separation of the hard segment and the elastomeric 
soft segment.' In most of the biomedical polyurethanes, 
the hard segment is usually composed of methylene 
diphenyl diisocyante (MDI), 1-4 butanediol, or diamine 
(chain extender). The soft segment is usually composed 
of polytetramethylene oxide (PTMO). Depending upon 
the composition of the above-mentioned reactants, the 
polyetherurethanes (PEUs) are useful in a variety of 
applications including fabrication of various types of 
blood contacting devices such as vascular prostheses, 
catheters, pacemaker leads, artificial hearts, heart valve 
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prostheses, and ventricular assist devices. However, 
the use of this material for long-term applications in 
cardiovascular implants is often hampered by calcification. 
Pathological calcification is defined as the deposition 
of calcium phosphates (chiefly hydroxyapatite) in ectopic 
sites, that is, sites other than normal mineralized tissue 
such as bone or dental mineral. Calcification is also the 
leading cause of failure of contemporary bioprosthetic 
heart  valve^.^ In vitro and in vivo calcification of bio- 
medical PEUs has been reported in the l i t e ra t~re .~-~  Be-
sides this, their stability and biocompatibility in vivo has 
been questioned. Hence the use of such materials in 
long-term implants such as cardiac valve prostheses and 
ventricular assist systems has been restricted. 
Prior work from our group"-'-l* and Golomb and 
Wagner13 demonstrated that sustained release of either 
the Na or Ca salt of hydroxyethanebisphosphonate 
(HEBP) from polymer matrices composed of materials 
such as ethylene vinyl acetate, polydimethylsiloxane, 
or polyurethane, prevent calcification with no side 
effects. This was due to local and low systemic 
dosage.'&14 In another related study from our laboratory, 
controlled release of the above HEBP salts from refillable 
PEU reservoirs was also found to inhibit calcification 
of rat subdermal pericardial bioprosthetic  implant^.'^ 
However, all of these studies were based on the 
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regional controlled release of HEBP. Once the agent 
has been exhausted from the matrices or reservoirs, 
the implanted material can begin calcifying. Thus, this 
strategy for preventing calcification is not an ultimate 
solution to avoid calcification of permanent cardiovascular 
implant. Therefore, our approach in this study was to 
characterize a new series of proprietary PEUs that contain 
covalently immobilized HEBP. No such materials have 
been previously considered. 
In the present studies, HEBP was covalently bound to 
a de novo synthesized PEU through a proprietary reaction 
mechanism. The objectives of these investigations were: to 
assess the stability of the bound HEBP (with comparison 
to HEBP-disperison); characterize (surface and bulk) the 
modified polymers; evaluate and compare in vitro calcium 
transport properties of the modified and control PEUs; and 
in vivo assessment of inhibition of calcification using a rat 
subdermal model. 
MATERIALS AND METHODS 
Materials 
A de novo proprietary synthesized medical grade polyure- 
thane (PEU) (CarboMedics, Austin, TX) was derivatized 
by covalently binding 100 to 500 nMlmg of the anti- 
calcifying agent HEBP. The anticalcifying agent was 
isolated and purified from Dequest 2010 (Monsanto Co., 
St. Louis, MO) by concentrating this solution through the 
evaporation of Dequest 2010 raised to boiling temperature, 
followed by seeding the saturated solution with acid 
HEBP crystals. I4C geminal carbon atom labeled disodium 
1,l hydroxyethylidene bisphosphonate (Na2HEBP) (spe- 
cific activity 144 pcurie/mL) was provided by Procter 
and Gamble, Inc. (Cincinnati, OH). Anhydrous tetrahydro- 
furan (THF) and other anhydrous solvents used during the 
experimental work (Aldrich Chemical Co., Milwaukee, 
WI) were used as received without any further purifica- 
tion. Ecolume counting cocktail (ICN Biomedical Inc., 
Irvine, CA) was used for all liquid scintillation studies. 
HEPES (N-[hydroxy ethyl] piperazine-N-[ethane sulfonic 
acid]) and Trizma (tris[hydroxymethyl] amino methane) 
(Sigma, St. Louis, MO) buffer was used for in vitro 
release studies. Biomer' (Ethicon, Somerville, NJ), and 
Mitrathane' (Polymedica, Denver, CO) medical grade 
PEUs (polyetherurethane urea) supplied 25% solution in 
dimethyl acetamide were used as received without any 
further purification. 
HEBP-Binding Stability: In Vitro Release Study 
Typically, five PEU films (1 cm2) containing covalently 
bound and physically dispersed I4C HEBP were indi- 
vidually incubated at 37 "C in 5 mL of physiological 
buffer (0.05 M HEPES at pH 7.4) with constant stirring 
(100 rpm) by using an orbital shaker (Lab Line, Melrose 
Park, CA). At specified time intervals over the 365- 
day release period, the releasate was exchanged and 
analyzed by combining it with 15 mL of Ecolume and 
then counted for I4C activity using a Beckman liquid 
scintillation counter (Model 3801, Berkeley, CA). The 
release profiles of HEBP from the PEU films were plotted 
as the cumulative amount of HEBP retained versus time. 
In Vitro Ca2+ Diffusion Studies 
The diffusion of the calcium across the underivatized and 
derivatized (unimplanted) membranes was studied using 
acrylic two-cell diffusion chambers. After measuring the 
thickness at five different points (0.2 2 0.0038 mm thick) 
the membrane was mounted between the two cells (n = 
4). The donor cell contained at 45% solution of calcium 
chloride, and the receptor cell contained 0.05M (pH 7.4.) 
Trizma buffer. The diffusion chambers were placed on an 
orbital shaker at 120 rpm at 37 "C. At each time point, the 
receptor cell was totally evacuated, rinsed with deionized 
double distilled water, and replenished with fresh buffer. 
Data were plotted as the cumulative calcium diffused (pg) 
as the function of time (days). 
In Vivo Studies 
Sample Preparation. The base polymer Mitrathane' 
dissolved in THF was cast on Teflon (A1 plastics, Austin 
TX) into sheets approximately 0.035-cm thick. After 48 h 
drying at 70 "C under vacuum, the Mitrathane' was cut 
into 1 cm2 pieces. The test polymers, namely HEBP 
derivatized (containing 100 nM of covalently bound 
HEBP), Biomer', and Mitrathane', were individually 
coated over the Mitrathane' by dipping into a solution 
of each test polymer to a final thickness of 0.0381 cm 2 
10%. The coated samples were dried at 125 "C for 1 h to 
remove any residual stress. 
Implant Procedure. Male weanling rats (50-60 g, 
CD Sprague Dawley, Charles River Laboratories, Burling- 
ton, MA) were anesthetized using ketamine (Parke Davis, 
Morris Plains, NJ; 0.057 mg/g) and xylazine (Haver, 
Shawnee, KA; 0.008 mg/g) as described e1~ewhere.l~ 
The test polymer samples were implanted into these 
anesthetized rats in subcutaneous pouches dissected in 
the ventral abdominal wall. The implant duration was 
60 days. Animals were maintained on Lab Chow Ralston 
Purina, St. Louis, MO) during the study. The animals were 
weighed prior to implant and then they were sacrificed. 
The explanted polymer samples were characterized for 
surface and bulk properties. 
Methods 
Representative explanted samples from each group were 
prepared for material analyses by washing (pH 1.8) with 
0.6% pepsin to remove surface adsorbed proteins, and 
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were then analyzed for surface and bulk properties. The 
changes in the materials were evaluated by comparison 
with pepsin-washed unimplanted control samples. Three 
samples per formulation were analyzed and the mean re- 
sults were taken into account for interpretation of the data. 
Electron Spectroscopy for Chemical Analysis. Elec- 
tron spectroscopy for chemical analysis (ESCA) were 
obtained on a Perkin-Elmer 5400 (Eden Prairie, MN). 
The underivatized, derivatized, and implanted derivatized 
PEU samples were fixed on the sample holder by double- 
sided tape, and degassed for 24 h under high vacuum. 
A 5 eV electron flood gun was used to offset charge 
accumulation on the sample. Elemental compositions were 
determined on the basis of the areas under each electron 
spectra curve from the corresponding element present in 
the sample at a pass energy of 150 eV. To prevent inelastic 
scattering, the analyses were performed under vacuum 
( lo7 - 10' torr). 
Fourier Transform Infrared Spectroscopy-Attenu- 
ated Total Reflectance. Fourier transform infrared spec- 
tra of the samples were measured by attenuated total 
reflectance spectroscopy (FTIR-ATR) using a Nicolet 5- 
DXC spectrophotometer (Nicolet, Model 60SX, Wiscon- 
sin, MD). The variable angle ATR attachment was used 
with a KRS-5 parallelogram crystal (50 * 10 * 3 m3). 
the films were placed in between the crystal. All spec- 
tra were the results of an accumulation of 200 scans 
collected at a resolution of 2 cm-' at a 45" angle of 
incidence after subtracting from the spectra of the glue. 
All spectra were recorded under similar identical condi- 
tions, and were corrected for atmospheric water vapor 
and carbon dioxide transmittance by subtraction of the 
appropriate reference spectrum. The air-cast surfaces of 
the underivatized and derivatized films were scanned for 
the analysis. 
Scanning Electron Microscopy (SEM) and Energy 
Dispersive X-Ray Spectroscopy (EDX). The air dried 
surfaces of each type of specimen (0.2 ? 0.0038 mm 
thick), were characterized by SEM (Hitachi Model S-570, 
Santa Clara, CA) and EDX (Kevax-8000, Foster City, CA) 
after sputtering with graphite under vacuum. A 150 mtorr 
vacuum with a current density of 20 mA and 1500 V 
was used to develop an -15-nm thick layer of graphite 
coating. 
Gel Permeation Chromatography (GPC). GPC of the 
samples was performed using a Waters liquid chroma- 
tography system (Model No. 440, Waters, Milford, MA) 
attached with a UV detector. The styragel columns (cross- 
linked styrene-divinyl benzene packing material) with 
pore size of lo2, lo3, and lo4 A attached in series were 
used. The flow rate of the degassed THF mobile phase 
was 1 .O mL/min. Monodispersed polystyrene standards 
dissolved in THF were used to calibrate the system. 
Results were expressed as relative molecular weight 
values. 
Water Uptake Studies. The water absorption capacity 
of the samples were determined by immersing the 
sample film (1 cm2, 0.2 2 0.0038 mm thick) in deioni- 
zed double distilled water at 37 "C for 72 h. The 
absorbed water content of each specimen was evaluated 
from the weight difference before and after 72 h 
immersion. 
Quantitative Calcium and Phosphorus Analyses. 
Explanted samples and unimplanted samples were quanti- 
tatively analyzed for mineralized calcium and phospho- 
rous elements by hydrolyzing samples freeze dried to 
a constant weight in 6 N HCl at 100 "C for 24 h to 
dissolve and elute all the mineralized elements adsorbed 
or absorbed. The hydrolysate was appropriately diluted for 
calcium and phosphorus analysis. The total calcium level 
was determined by using atomic absorption spectroscopy 
(AAS) (Perkin-Elmer 2380, Norwald, CT). l6  Phosphorus 




Solution containing 40 to 45% (w/v) of the above 
PEUs were prepared in polar solvents such as THF 
and dimethyl acetamide (DMAc). These PEUs were 
readily soluble forming translucent solutions. To speed 
the dissolution at room temperature, the polymer 
sample mixture on stirring resolved as a single 
phase and was free of gel particles or cloudiness. 
However, the relative rate of dissolution differed for 
all samples. The relative order of solubility observed 
was derivatized (explanted) > derivatized (control) > 
nonderivatized. This suggests that some change in the 
bulk property of the polymer occurred on derivatization 
and implantation. Explanted Mitrathane@ samples, when 
combined with DMAc solvent, disintegrated forming a 
turbid solution. This might be due to the degradation 
of the polymer and extensive mineralization (see 
following). 
HEBP-Binding Stability: In Vitro Release Study 
The comparative release of HEBP covalently bound to 
PEU versus HEBP physically dispersed in PEU was 
verified by monitoring the release kinetics of radiolabeled 
HEBP. Figure 1 illustrates the release profile for deriva- 
tized polyurethane containing 45.5 2 2.3, 86.2 5 1.1, 
and 398.7 t 2.2 nM of HEBP covalently bound, and 
458.17 2 1.3 nM of HEBP physically dispersed in the 
polymer. HEBP covalently bonded to PEU when moni- 
tored for 365 days demonstrated that more than 75% of 
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Figure 1. Release profile (residual) of covalently bound compared to physically dispersed HEBP (nM/rng) from polyurethane (PEU) films. 
the total anticalcifying agent originally incorporated in the 
polymer was still present. The initial 25% of nonbound 
HEBP released from derivatized samples during the first 
2 weeks might be due to the diffusion of the unreacted 
HEBP, or due to the dissociation of low molecular weight 
HEBP containing oligomers from the polymer matrix. 
After this initial release, the derivatized films attained 
an equilibrium during which no further detectable HEBP 
release was seen (Fig. 1). 
However, when PEU matrices containing physically 
dispersed HEBP were incubated at 37 "C, an initial release 
of 26% in the first 24 h was observed followed by 
34% release in the next 60 days. The remaining 40% 
of the noncovalently bound HEBP continued leaching 
out slowly and continuously from the films (Fig. 1). 
In this case the PEU matrix behaved like a sustained 
release preparat i~n, '~- '~  which will hypothetically prevent 
calcification for a limited period of time. 
Calcium Diffusion Studies 
The results of the calcium diffusion studies comparing 
underivatized and HEBP derivatized membranes are de- 
picted in Figure 2. It can be noted from these curves 
that in the first 24 h of diffusion, the cumulative amounts 
of calcium diffused across the underivatized membranes 
was found to be 5.93 2 3.2 pg .  But after 24 h these 
membranes attained equilibrium during which a steady 
diffusion of calcium was observed with an average dif- 
fusion of 3.742 ,ug/day. HEBP derivatized PEU demon- 
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strated 50% or less Ca2+ transport than control. The 
calcium diffusion decreased with increasing amounts of 
covalently bound HEBP. The overall presence of HEBP 
in the PEU appears to significantly retard the transport 
of calcium ions and this implies that covalent binding 
of HEBP to the PEU does indeed interact with ionized 
calcium. 
In Wvo Studies 
In general, explanted non-HEBP derivatized samples ap- 
peared to be yellowish and somewhat opaque. HEBP- 
derivatized explants retained their preimplant, translu- 
cent appearance. Although Mitrathane@ (control) rat 
subdermal explants showed the highest amount of 
mineral deposition (Ca = 12.6 2 0.9 and P = 7.9 5 
0.8 pg/mg), HEBP-PEU (100 nM HEBP/mg of PEU) 
coated over Mitrathane@ showed no detectable calcium. 
The phosphorus detected in the HEBP derivatized 
unimplanted samples (P = 0.6 2 0.2pg/mg) and deri- 
vatized explanted (0.2 2 1.6 pg/mg) was probably con- 
tributed by HEBP incorporated in the polymer. The 
variation in this phosphorus content might be due to 
the leaching of some unreacted phosphonate (HEBP) 
~~ 
-0- PEU (underivatimd) 
-0- PEU ( 1 0 0  nWmg of HEBP) 
-M- PEU (200 nM/mg of HEBP) 
-f- PEU (300 nM/mg of HEBP) 
* PEU (400 nM/mg of HEBP) 
* PEU (500 nM/mg of HEBP) 
/ 
50  100 150 200 
Time (Hours) 
Figure 2. Comparison of cumulative calcium diffusion across the underivatized and HEBP derivatized (covalently bound) PEU membranes. 
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or low molecular weight oligomers during implantation. 
Biomer' demonstrated significantly less calcium phos- 
phate deposition (Ca = 1.2 ? 0.8 ,ug/mg and P = 0.6 % 
0.1 pg/mg and P = 0.6 2 0.1 pg/mg) than Mitrathane' 
For comparison, calcification data (Table I) on subder- 
ma1 implanted glutaraldehyde cross-linked pericardium 
demonstrated the more severe nature of calcification of 
this type of material compared to polyurethane. Thus, 
these results have demonstrated that covalent binding 
of the HEBP to the polyurethane significantly inhibited 
PEU calcification in rat subdermal implants compared to 
Biomer' and Mitrathane' controls. 
SEM/EDX 
Figure 3(a) and (b) shows the SEM and EDX of the 
explanted (60 days rat subdermal studies) Mitrathane@ 
coated with Biomer' and HEBP-PEU (containing 
100 nMlmg). The unimplanted control polymer samples 
analyzed by SEM typically showed surfaces with small 
pits dispersed randomly, probably due to the rapid 
evaporation of the solvent or due to the migration of the 
additives during casting. '* On implantation a remarkable 
change was observed in the surface morphology of the 
samples. Surface erosion or degradation was evident in 
all test samples. Mitrathane' showed extensive surface 
cracks and fissure formation on the surface probably 
indicating the degradation of the polymer on the surface. 
Similar results have been previously reported by other 
researchers in the However, Biomer@ showed 
a large difference in surface morphology compared 
to Mitrathane'. The Biomer' surface was found to 
show cavities instead of cracks and fissures. Explanted 
HEBP derivatized PEU samples also showed more or 
less the same type of surface changes as noted with 
Biomer'. 
The EDX spectra of the implanted Mitrathane' and 
Biomer' samples demonstrated the presence of calcium 
and phosphorus. Figure 3(a) and (b) also shows the EDX 
spectrum of Mitrathane' and HEBP modified PEU. The 
mineral components were shown to be only on the sur- 
face of the sample and not in the bulk of the poly- 
mer. Figure 3( b) (backscattering electron image) of HEBP 
modified polymer also shows cracks that might be due to 
SEM artifact or biodegradation. Distinguishing between 
these possibilities was beyond the scope of the study. No 
calcium was detected on the surface of HEBP modified 
PEU explants. However, the phosphorus was found to 
be present on the surface of these samples, and was 
presumably contributed by the HEBP. 
ESCA 
This surface analysis technique, sensitive to depths of 30 
to 100 A, provides qualitative and quantitative elemental 
composition at an atomic level, and also in part delin- 
eates the nature of binding based on the chemical shifts. 
Tables I1 and I11 give the percentage contents of each el- 
ement and C1, peak components based on the relative 
area of each peak. The CIS high-resolution ESCA spectra 
of the underivatized and HEBP derivatized polyurethane 
(unimplanted and implanted) was deconvoluted into three 
main species, that is C-C (285.0 eV), C-0 (286.4 eV), 
and N-COO (289.5 eV) carbons using the assumption 
of 80% Gaussian and 20% Lorenzian peak shapes. The 
results are consistent with the nonderivatized sample be- 
ing mainly composed of a poyether-type soft segment 
because the content of ethereal (C-0) carbon is much 
higher than that of urethane (N-COO) carbon. But on 
derivatizing with HEBP, ClS binding energies of the three 
species (285.0, 286.75, and 289.40 eV) were all found 
to differ slightly from the nonderivatized PEU sample. 
The C1, peak components of the ether species increased 
and appeared as a small shoulder peak, whereas the main 
hydrocarbon peak decreased. The urethane (N-COO) 
carbon was found to be the same as the underivatized 
sample. On subdermal implantation of derivatized PEU 
in rats, the C1, peak components of the ether species 
TABLE 1. Calcium and Phosphorus Content of Rat Subdermal Implants (60 days) and Unimplanted Materials 
Ca'* SE ~ 0 ~ 3 -  SE Ratio 
Polymer n(cLs/md ( 2 )  (pug/mg) ( 2 )  (Ca/P> 
Implanted 
Mitrathane@ 10 12.6 0.86 7.89 0.78 1.59 
PEU 10 0.24 0.04 0.14 0.07 1.63 
GBP 10 226.90 0.87 180.5 0.18 1.26 
Mitrathane@ (C) 4 0.15 0.00 0.02 0.00 7.62 
B i o m e r @ 10 1.22 0.17 0.55 0.09 2.21 
Unimplanted 
Biomer@ (C) 4 0.1s 0.00 0.03 0.00 5.70 
PEU (C) 4 0.14 0.00 0.64 0.00 0.22 
GBP 4 0.33 0.00 0.21 0.00 1.60 
~~ 
C. control sample; 100 = 100 nM of EHDP covalently bound; GBP, glutaraldehyde pretreated bovine pericardium; n. number of samples used for analyses. 
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Back Scattering Electron Image Samning Electron Microscopic Image P 
I '  
Figure 3(a). Scanning electron microscopy (SEM)/energy dispersive x-ray (EDX) of Mitrathane@ 
implanted sample in rat for 60 days. 
Scanning Electron Microscopic Image 1 BnckstatteringElectronImage 
Figure 3( b). Scanning electron microscopy (SEM)/energy dispersive x-ray (EDX) of PEU 
(100 nM/mg HEBP) implanted sample in rat for 60 days. 
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TABLE II. ESCA of Various Elements Present 
on Surface of Phosphonated PEU 
Elements Present (%) 
Polymer Code c,, 01, Nl, SiZP P Z P  
implanted Mitrathane@ samples showed relatively more 
prominent changes demonstrating in the peak intensities 
(compared to unimplanted) than did the implanted 
Biomer' samples. 
PEU (underivatized) 79.0 19.3 1.7 ND ND 
PEU (derivatized) 76.1 21.6 1.9 1.27 ND 
PEU (implanted derivatizcd) 72.6 23.5 3.3 0.7 ND 
ND. Not detected. 
decreased and that of the main hydrocarbon and urethane 
(N-COO) carbon peaks uncreased and these results may 
be explained by phase reversal. 
FTIR-AIR 
Figure 4(a), (b), and (c) shows the FTIR-ATR spectra of 
underivatized, HEBP derivatized unimplanted, and HEBP 
derivatized explanted polyurethane samples containing 
100 nM of covalently bound HEBP. The characteris- 
tic peaks of each of the major transmittance bands is 
described in Table IV. Comparisons of unimplanted un- 
derivatized and derivatized PEU show remarkable changes 
in peak positions and intensities of prominent peaks 
such as the amide I and IT, carbonyls and ether peaks. 
The amide I peak became broader and shifted 15 cm-' 
downfield and the intensity of the bonded carbonyl de- 
creased and that of the ether peak increased. The in- 
tensity of some of the peaks in the fingerprint region 
was found to increase on derivatization. Overall the in- 
tensity of the peaks corresponding to the soft segment 
were found to be more prominent than the hard seg- 
ment. 
On subdermal implantation (rats, 60 days), the spectra 
when compared to derivatized unimplanted controls 
showed a significant change in the peak pattern and 
position corresponding to hard and soft segments. The 
intensity of the hard segment peaks was found to have 
increased as compared to HEBP derivatized unimplanted 
controls. Two new small peaks at 1174 and 771 cm-' 
related to oxidative degradation*' were detected in 
the derivatized implanted samples identified as ester 
functionalities. Biomer' and Mitrathane@ (unimplanted 
and explanted samples) showed a remarkable change in 
the peak positions and intensities corresponding to hard 
and soft segments. Before implantation, the derivatized 
unimplanted control sample showed the surface to be 
rich in soft segment components, and after implanting 
demonstrated a relative hard segment enrichment. The 
TABLE 111. ESCA CIS Peak Components 
Water Absorption Studies 
The water absorption capacity of the underivatized and 
derivatized samples with different compositions of cova- 
lently bound HEBP showed increasing water absorption 
with increases in the level of incorporation of bisphos- 
phonate. The increased hydrophilicity of the derivatized 
samples could be attributed to the incorporation of HEBP 
in the polymer matrix. This increase in hydrophilicity 
could hypothetically contribute enhancement of the non- 
thrombogenicity of the polymer.22 
GPC. Table V shows the molecular weight data for 
the various polymers samples analyzed before and after 
implantation. In the case of the HEBP-derivatized unim- 
planted PEU, the M ,  decreased by 8.1 and M ,  by 
0.65%, respectively, as compared to underivatized PEU. 
On implanting, M ,  decreased by 9.69% and M, 21.18% 
compared to underivatized PEU. The dispersity (MWD) 
was found to have increased on derivatization and implan- 
tation. The implanted Biomer@ demonstrated a decrease of 
15% from M,, 35% for Mw,  and 24% for MWD compared 
to unimplanted. Similarly, implanted Mitrathane@ showed 
a decrease of 10.5% for M, and 12.5% for MWD, respec- 
tively. However, the M ,  of the implanted Mitrathane' was 
found to have increased by 2.5%. 
DISCUSSION 
Our present investigation was focused on the anticalcifica- 
tion efficacy of HEBP covalently bound to polyurethane. 
The principal findings of this study were: 
Covalent binding of HEBP to the proprietary synthe- 
sized polyurethane was stable and efficient. 
ESCA and FTIR-ATR studies demonstrated the incor- 
porated HEBP to be associated with the soft segment. 
Diffusion of calcium solution through the derivatized 
polymers decreased with increasing levels of covalent 
bound HEBP. 
There was an anticalcification effect of covalently 
bound HEBP when compared to Biomer' and 
Mitrathane' as demonstrated by calcium analyses of 
the rat subdermal explants. 
Polymer Code c-c (%) c-0 (%) N-COO (%) C-O/N-COO (%) 
PEU (underivatized) 59.4 38.6 1.7 22.70 
PEU (derivatized) 58.9 39.4 1.7 23.17 
PEU (implanted derivatized) 61.0 34.2 4.9 6.97 
PHOSPHONATED POLYURETHANES THAT RESIST CALCIFICATION 73 
8 
o i  I 
4000 2000 400 
Wavenumbers 
Figure 4. FTIR-ATR spectra of (- - -), (-) derivatized unimplanted 
PEU, and (- . - . -) in rat for 60 days. 
Calcification of bioprosthetic or synthetic heart valves 
is the most frequent cause of clinical failure. Prevention of 
this pathophysiological event is possible by either altering 
the implant through pretreatment procedures or through 
the therapeutic administration of an anticalcification agent. 
The former technique may deleteriously affect the physical 
and chemical properties of the material and biological 
properties of the prostheses, whereas the later may have 
untoward side effects on normal metabolism and bone 
physiology. Most of the work published in the literature 
concerned with inhibition of implant calcification has been 
on the modification of porcine aortic valve bioprostheses. 
Recently, the use of commercially available medical grade 
PEUs, such as Biomer@, Mitrathane@, and Pellethane@ 
have been evaluated for various cardiovascular appli- 
cations such as artificial heart devices and heart valve 
prostheses. However, these polymers are also reported 
to calcify either in vitro or in vivo or Although 
the pathogenesis of PEU calcification is different from 
that reported for bioprosthetic heart valves, the principal 
mineral phase component of calcification is most likely 
hydroxyapatite in both types of mineralization. Calcifica- 
tion results in loss of important physical, chemical, and 
biological properties of the implant eventually leading to 
its failure. 
Previous studies from our group have demonstrated 
that local site-specific therapy with controlled release 
HEBP-polymers and HEBP-glutaraldehy de pretreated bio- 
prosthetic heart valve (BPHV) prevented calcification 
in rat subdermal implants with no side  effect^.'^-'^,^^-^^ 
However, this method is limited by the duration of sus- 
tained HEBP release. The exact mechanism of inhibi- 
tion of physiological and pathological calcification by 
HEBP is still incompletely understood. Some believe 
HEBP prevents calcification by steric chemoabsorption 
to calcium phosphate nuclei, leading to the inhibition 
of further crystal growth, whereas others have reported 
HEBP to behave as a detergent, by decreasing the number 
of available nucleation sites for hydr~xyapatite.~ Others 
have suggested that HEBP may act by inhibiting alkaline 
phosphata~e.~ 
HEBP-Binding Stabi1ity:In Vitro Release Study. The 
results of in vitro studies performed for more than 1 
year demonstrated that a majority of the initial cova- 
lently incorporated HEBP remained in the polymer. If the 
HEBP had not been covalently bound (versus physically 
dispersed) to PEU, it would be expected to have con- 
tinuously diffused from the polymer until the physically 
dispersed HEBP was exhausted through diffusion and 
thus, calcification would have resumed. This study further 
removes doubts that the reacted bisphosphonate could 
have simply become entrapped in the polymer matrix 
by various physical forces such as hydrogen bonding, 
Van Der Walls force of attraction. However, gradual 
HEBP release would have been expected had there not 
been permanent binding to the polymer chain. 
Calcium Diffusion Studies 
Based on our calcium diffusion studies, the presence of 
HEBP in the PEU greatly reduces the immediate calcium 
influx. Therefore, covalently bound HEBP could hypo- 
thetically retard the kinetics of initial crystalline calcium 
phosphate formation by inhibiting calcium permeation. 
This could be explained as follows: It has been reported 
that HEBP forms polynuclear aggregates with calcium 
ions under physiological conditions.26 Although the exact 
mechanism of the calcium-HEBP aggregation is still not 
clearly understood it is suggested to take place through the 
aliphatic alcoholic and the neighboring two phosphonic 
acid groups and thus hinders the attraction of phos- 
phate ion for further crystallization of calcium phosphates. 
The PEU-HEBP membranes in our studies could be 
binding calcium ions and thereby blocking nucleation 
sites thus preventing the diffusion of calcium ion either 
through charge repulsion or by blocking theoretical mole- 
cular pores. 
In Vivo Studies 
The results from the in vivo studies have clearly indi- 
cated that covalent HEBP incorporation was effective 
in preventing calcification in rat subdermal implants as 
compared to controls (Biomer@ and Mitrathane@). ESCA 
and FTIR-ATR results did not detect HEBP on the surface 
of the explanted derivatized polymer, despite the sig- 
nificant anticalcification activity of the HEBP-derivatized 
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TABLE IV. Principal ATR-FTIR Peak Assignment for Polyurethane 
Wave Number 





































v (N-H) free NH 
v (N-H) bonded NH 
v (CH,) in ET only 
v (CH,) in ET only 
v (CH,) in ET only 
v (C= 0) free C= 0 
v (C= C) in benzene ring 
v (C-C) in benzene ring 
6 (NH) + n (C-N) 
(CHZ) 
6 (NH) +n (C-N), b (C-H) 
CH2), n (C-0-C) in -C-0-C- 
II 
0 
6 (NH) +a (C-N) 
v (C-0-C) or n (Si-0-Si) aliphatic 
ether 
v (C-0-C) in hard segment (C-0-C) 
II 
0 
fi  (C-H) in benzene ring 




Y, stretching; 6, bending; p,  in plane bending; y out of planc bcnding; w ,  wagging; W, weak; Sh, shoulder; S, sharp; M, medium; VS, very sharp. 
polymer and the continued presence of HEBP based on 
the radioactive release results. This might be due to the 
phase change taking place on implantation, resulting in 
a subsurface location of the covalently bound drug or 
alternatively, the surface concentration of HEBP may 
be below the detection limits of our instrument. The 
detection of phosphorus on the surface of the HEBP-PEU 
implanted sample by SEM-EDX with no sign of calcium 
presence either on the surface or bulk of the polymer 
may indicate that the incorporated HEBP migrated onto 
the surface on implantation. Cracks seen on the surface 
in Figure 3( b) (backscattering electron image) might be 
due to SEM artifact. Further investigation of the nature of 
these surface images in the HEBP modified polymers will 
be done in the future. As seen in results of the explanted 
Biomer@ and Mitrathane@ samples, increased calcium and 
phosphorus was detected and confirmed by elemental 
analysis. Furthermore, the nucleation of calcification as 
seen from the SEM studies identified to be a surface 
phenomenon with no mineralization detected in the bulk 
of the polymer. 
ESCA 
Although no direct evidence for the presence of HEBP on 
the subsurface of the modified polymer could be obtained 
by ESCA, indirect evidence for its incorporation as a 
soft segment was demonstrated by the changes in the 
peak pattern, position, and intensity of the spectrum. The 
C1, binding energies of three possible carbon domains 
(285.0,286.75, and 289.40 eV) of derivatized unimplanted 
PEU were found to be slightly inconsistent as compared 
to the nonderivatized PEU sample. This might be because 
of the incorporation of the bulkier HEBP group into 
the polymer chain causing differences in the electronic 
distribution around C-0 species resulting from a shifting 
of the peak to a higher binding energy. The increase in 
oxygen atomic composition as shown in Table I1 and the 
ethereal (C-0) carbon as shown in Table 111, probably 
indicate that the incorporated HEBP forms an ether type 
of linkage and is distributed in the soft segment of the 
polymer matrix. This is confirmed by the increase in 
the ratio of the percent C-O/N-COO. The implanted 
sample showed carbamate rich (N-COO) hard segment 
species suggesting a loss of ether linkages either due to 
degradation or due to the phase change of segments fol- 
lowing an exposure to the pepsin solution used to remove 
the surface-adhered proteins or possibly during the storage 
of the samples following ex plant^.^^-^^ The decrease in 
the ratio of percent C-O/N-COO further confirms the 
surface to be rich in hard segment of phosphorus peaks in 
all the derivatized (unimplanted and implanted) samples 
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indicates (as discussed above) that either the phosphonate 
groups might be buried in the bulk, or more likely that 
the amount of phosphonate incorporated into the polymer 
was beneath the detection limits. 
FTIR-ATR 
FTIR-ATR spectroscopic studies revealed no phosphorus 
peaks in the expected region, around 1100 cm-', and 
this may be due to the fact that some of the peaks 
corresponding to the polymer also fall in the same region. 
However, comparing relative intensities of peaks in the 
region where the phosphonate peak might be expected 
to appear, a prominent change in peak position and 
intensity was noted. On derivatization, the 1100 cm-' 
peak shifted in the range of 40 to 50 cm-' upfield. This 
region usually identified as a polyether peak, indicates that 
the covalent binding the HEBP through the proprietary 
reaction mechanism leads to an ether type of linkage and 
thus the HEBP is dispersed in the soft segment of the 
polymer matrix. Because of the incorporation of HEBP 
in the polymer chain as a soft segment, a noticeable 
change in hydrogen bonding is observed. Spectra of HEBP 
derivatized PEU showed the NH band, which is strongly 
hydrogen bonded in nonderivatized PEU, to have a broad 
shoulder peak, a decrease in band intensity, and an upfield 
shift of 55 cm-'. This can be explained by the possible 
rupture of hydrogen bonding between the NH group 
arising from the hard segment and the ethereal or carbonyl 
oxygen group, probably resulting in hydrogen bonding 
between the phosphonate and ether linkage because of the 
electronegative nature of HEBP. Such an effect implies 
that incorporation of HEBP in the polymer chain resulted 
in a plasticization-like effect in the bulk of the polymer 
causing a phase separation. 
In nonderivatized PEU, the NH-I1 amide band in the 
region of 3325 cm-' appears to be completely hydrogen 
bonded, which is probably due to the hydrogen bond 
TABLE V. Molecular Weights of Polyurethanes 
Coated on the Surface of Mitrathane@: Results 
Before and After Implantation 
Polymer Code M" M w  MWD 
formation between the NH group from the hard segment 
and ether-oxygen or the carbonyl-oxygen from the soft 
segment or both. This suggests that there is complete 
phase mixing in this newly synthesized medical grade 
polyurethane. On covalent binding of HEBP through 
the proprietary reaction (derivatized), the NH-I1 amide 
band appeared with a broad shoulder peak, decreased in 
band intensity, and shifted upfield by 30 to 55 cm-' as 
compared to the underivatized PEU. This indicates that 
the hydrogen bonding must have been disturbed due to the 
incorporation of bulkier HEBP resulting in a phase change 
confirmed by the increase in carbonyl hydrogen bonding 
peak. The increase in the ratio of the peak intensities of 
the bands at 1102 cm-' (C-0-C), representing the 
soft segment concentration, and the band at 1080 cm-' 
(CO-0-C) representing the hard segment concentra- 
tion, further confirms that the incorporated HEBP behaves 
as a soft segment in the polymer matrix. 
On explanting (rat subdermal, 60 days) the deriva- 
tized PEU containing 100 nM of covalently bound 
HEBP showed a considerable change in peak inten- 
sities for the peaks representing the soft segments 
(966,1110,1367,2796, 2856, and 2939 cm-') and hard 
segments (771,1066,1221,1310,1412,1539,1639, and 
3320 cm-'). The hard segment peaks were found to 
be more pronounced in the explanted sample with 
respect to those representative of the soft segment. These 
results suggest that either the hard segment moving 
to the surface, or a loss of soft segment on the 
surface (perhaps through phase reversal) are the most 
likely explanations for the spectral changes observed. 
The latter possibility is supported by ESCA studies. 
Besides the increase in hard segment concentration on 
the surface, an increase in hydrogen bonding was also 
noted. This might be due to the formation of more 
hydrogen bonding functionalities on implanting. Two new 
small peaks at 1174 and 771 cm-' were detected in the 
derivatized implanted samples suggesting an increase in 
ester functionalities that might be due to the oxidation of 
the ether linkages indicating that HEBP may not retard 
surface oxidation. Thus, these results could indicate that 
some surface changes occur on implantation leading to 
the surface becoming relatively enriched in hard segment 
concentration. 
Biomer@ 
Unimplanted 1.27 * lo6 6.67 * lo6 5.24 
Explanted 1.08 * 10' 4.30 * lo6 3.96 
Mitrathane@ 
Unimplanted 6.07 * lo5 2.39 * lo6 3.93 
Explanted 6.22 * lo5 2.14 * lo6 3.44 
PEU 
Unimplanted 9.74 * lo5 2.65 * lo6 2.72 
Derivatized 7.91 * lo5 2.42 * 10' 3.03 
Explanted 6.72 * lo5 2.65 * 10' 3.53 
M,, Number average molecular weight; M,, weight average molecular weight; 
MWD, molecular weight dispersion; PEU contain 100 nM of covalently bound HEBP. 
Water Absorption Studies 
The derivatized polymers, which were found to be more 
hydrophilic than the underivatized polymers, may handle 
water differently due to the incorporation of HEBP as 
part of the soft segment in the polymer chain. The 
increased hydrophilicity of the derivatized polymer might 
also contribute to the thromboresistance.22 In a previous 
study by G ~ l o m b , ~ '  it was reported that the porosity 
and water absorption capacity of PEU may increase the 
potential for calcification in rat subdermal implants. How- 
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ever, the present HEBP derivatized materials, which were 
increasingly hydrophilic in nature with increased amounts 
of incorporated HEBP, had no calcification following rat 
subdermal implantation. 
GPC 
The HEBP modified PEUs showed negligible changes in 
bulk properties. When tested for solubility in various polar 
solvents, the derivatized PEUs dissolved relatively more 
slowly than the control samples because of the slight 
increase in molecular weight as seen from GPC data. 
The slight increase in Mn and a large increase in Mw 
indicates that the polymer molecule may have undergone a 
coupling reaction between large and small polymer chains 
on covalent binding of HEBP. The increase in dispersity 
could also be attributed in part to formation of some low 
molecular weight oligomers or unreacted HEBP during the 
binding reaction as seen from the release kinetics study. 
SUMMARY AND CONCLUSIONS 
A series of proprietary medical grade PEU was 
successfully derivatized by covalent binding of 100 to 
500 nM/mg of HEBP through a proprietary reaction 
mechanism. Based on the release kinetics studies, it can 
be concluded that the covalent binding of HEBP through 
the proprietary reaction mechanism is efficient, stable, 
and permanent. The bound HEBP is incorporated in 
the soft segment as demonstrated by ESCA and FTIR- 
ATR studies. The molecular weight of the modified 
polymer sample increased slightly, but the dispersity 
increased appreciably. This might be due to the binding 
of HEBP to the chains of various molecular weights 
within the polymer matrix. The water absorption of the 
modified PEU increased with increasing incorporation 
of bound HEBP. In vivo implanted samples showed 
a slight change in surface and bulk properties. The 
surface of the implanted sample becomes richer in hard 
segment concentrations. In vivo implantation resulted 
in a slight decrease in molecular weight, which might 
be due to the oxidation of the ether linkages or 
diffusion of low molecular weight. HEBP containing 
oligomers. Furthermore, the results of rat subdermal 
implants demonstrated that covalently bound HEBP 
was an effective means for inhibiting the calcification 
of polyurethanes. Thus, HEBP containing PElJ is a 
promising candidate for preparing cardiovascular implants 
that will resist calcification. 
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